Molecular Cancer Research Targeting the PI3-Kinase Pathway in Cancer Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Published online first on April 3, 2007
[Molecular Cancer Research, 10.1158/1541-7786.MCR-06-0353]
This Article
Right arrow Full Text (Online First [PDF])
Right arrow Supplementary Data, Chaturvedi, et al.
Right arrow All Versions of this Article:
1541-7786.MCR-06-0353v1
5/4/309    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chaturvedi, P.
Right arrow Articles by Batra, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chaturvedi, P.
Right arrow Articles by Batra, S. K.


Angiogenesis, Metastasis, and the Cellular Microenvironment

MUC4 Mucin Potentiates Pancreatic Tumor Cell Proliferation, Survival, and Invasive Properties and Interferes with Its Interaction to Extracellular Matrix Proteins

Pallavi Chaturvedi 1, Ajay P. Singh 1, Nicolas Moniaux 1, Shantibhushan Senapati 1, Subhankar Chakraborty 1, Jane L. Meza 3, and Surinder K. Batra 1, 2*

1Department of Biochemistry and Molecular Biology, 2Eppley Institute for Research in Cancer, and 3Department of Societal and Preventive Medicine, University of ebraska Medical Center, Omaha, Nebraska

* To whom correspondence should be addressed. E-mail: sbatra{at}unmc.edu.


   Abstract

MUC4, a transmembrane mucin, is aberrantly expressed in pancreatic adenocarcinomas while remaining undetectable in the normal pancreas. Recent studies have shown that the expression of MUC4 is associated with the progression of pancreatic cancer and is inversely correlated with the prognosis of pancreatic cancer patients. In the present study, we have examined the phenotypic and molecular consequences of MUC4 silencing with an aim of establishing the mechanistic basis for its observed role in the pathogenesis of pancreatic cancer. The silencing of MUC4 expression was achieved by stable expression of a MUC4-specific short hairpin RNA in CD18/HPAF, a highly metastatic pancreatic adenocarcinoma cell line. A significant decrease in MUC4 expression was detected in MUC4-knockdown (CD18/HPAF-siMUC4) cells compared with the parental and scrambled short interfering RNA-transfected (CD18/HPAF-Scr) control cells by immunoblot analysis and immunofluorescence confocal microscopy. Consistent with our previous observation, inhibition of MUC4 expression restrained the pancreatic tumor cell growth and metastasis as shown in an orthotopic mouse model. Our in vitro studies revealed that MUC4-associated increase in tumor cell growth resulted from both the enhanced proliferation and reduced cell death. Furthermore, MUC4 expression was also associated with significantly increased invasiveness (P ≤ 0.05) and changes in actin organization. The presence of MUC4 on the cell surface was shown to interfere with the tumor cell-extracellular matrix interactions, in part, by inhibiting the integrin-mediated cell adhesion. An altered expression of growth- and metastasis-associated genes (LI-cadherin, CEACAM6, RAC1, AnnexinA1, thrombomodulin, epiregulin, S100A4, TP53, TP53BP, caspase-2, caspase-3, caspase-7, plakoglobin, and neuregulin-2) was also observed as a consequence of the silencing of MUC4. In conclusion, our study provides experimental evidence that supports the functional significance of MUC4 in pancreatic cancer progression and indicates a novel role for MUC4 in cancer cell signaling. (Mol Cancer Res 2007;5(4):309-20)

Key Words: MUC4, Mucin, Pancreatic cancer, Proliferation, Survival




This article has been cited by other articles:


Home page
Cancer Res.Home page
P. Chaturvedi, A. P. Singh, S. Chakraborty, S. C. Chauhan, S. Bafna, J. L. Meza, P. K. Singh, M. A. Hollingsworth, P. P. Mehta, and S. K. Batra
MUC4 Mucin Interacts with and Stabilizes the HER2 Oncoprotein in Human Pancreatic Cancer Cells
Cancer Res., April 1, 2008; 68(7): 2065 - 2070.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
P. Chaturvedi, A. P. Singh, and S. K. Batra
Structure, evolution, and biology of the MUC4 mucin
FASEB J, April 1, 2008; 22(4): 966 - 981.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. V. Gold, Z. Karanjawala, D. E. Modrak, D. M. Goldenberg, and R. H. Hruban
PAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma
Clin. Cancer Res., December 15, 2007; 13(24): 7380 - 7387.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.